uploads/2018/05/tecfidera2.png

What Are Biogen’s Key Growth Areas?

By

Updated

Growth areas

In the neurological and neurodegenerative disease segments, Biogen’s (BIIB) targets include multiple sclerosis (or MS), Alzheimer’s disease (or AD), spinal muscular atrophy (or SMA), and amyotrophic lateral sclerosis (or ALS).

Biogen also plans to invest in growth areas like pain, ophthalmology, neuropsychiatry, and acute neurology. The company is also employing innovative technologies in order to discover potential treatments for rare and genetic disorders, which includes new ways of treating diseases through gene therapy.

Article continues below advertisement

Products on the market

The company’s products on the market include Tecfidera, Avonex, Plegridy, Tysabri, and Fampyra for the treatment of multiple sclerosis, Spinraza for the treatment of spinal muscular atrophy, and Fumaderm for the treatment of severe plaque psoriasis. Plus, Biogen also holds certain rights for Rituxan for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and other conditions and Gazyva for treating CLL and follicular lymphoma.

Karyopharm acquisition

In January 2018, Biogen acquired exclusive worldwide development and commercialization rights for Karyopharm Therapeutics’ investigational oral compound KPT-350. The drug is targeted for treating certain neurological and neurodegenerative conditions, mainly ALS. KPT-350, now called BIIB100, is a novel therapeutic candidate and is phase one ready.

In consideration, Biogen made an upfront payment of $10 million and also agreed to pay Karyopharm additional milestone payments of up to $207 million as well as potential royalties.

Performance in key target indications

In multiple sclerosis, Biogen’s products on the market include Tecfidera, Interferon, Tysabri, Fampyra, and Zinbryta. Total sales of tecfidera increased from $958 million in 1Q17 to $987 million in 1Q18. Sales of Interferon decreased from $648 million in 1Q17 to $550 million in 1Q18. This decrease was mainly attributable to a fall in the drug’s US revenues, which fell from $465 million in 1Q17 to $371 million in 1Q18. Sales of fampyra, which is sold outside the US, came in at $4.4 million in 1Q18 compared with $20.5 million in 1Q17, an increase of ~25%.

In the next part of the series, we continue to explore the performance of Biogen’s target indications.

Advertisement

More From Market Realist